import React, { useState } from "react";
import { Card, CardContent } from "./ui/card";
import { Button } from "./ui/button";
import { Avatar } from "./ui/avatar";
import {
  Users,
  MoreHorizontal,
  ThumbsUp,
  MessageCircle,
  Share2,
} from "lucide-react";

export function BlogPage() {
  const [posts] = useState([
    {
      id: "urn:li:ugcPost:1234567890123456789",
      author: {
        id: "urn:li:organization:987654321",
        name: "Bridge Medical",
        logo: "https://media.licdn.com/dms/image/v2/D4D0BAQGeVzHUMroZgg/company-logo_200_200/company-logo_200_200/0/1716200174821?e=1759968000&v=beta&t=_0zXxkhx5U6Tl33WRw3ylTX_X46i5QjlyLPf2QmSRMY",
        verified: true,
        title: "Medical Consulting",
      },
      created: "2025-09-08T10:15:00Z",
      lastModified: "2025-09-08T10:15:00Z",
      content: {
        text: "üß†‚ÄãLecanemab (Leqembi): A True Breakthrough in Alzheimer's Disease Treatment...\n\nüá™üá∫‚ÄãIn April of this year, the medical world received exciting news: the European Medicines Agency (EMA) approved Lecanemab (marketed as Leqembi) for the treatment of early-stage Alzheimer's disease. This marks a historic moment, as it's the first therapy in the European Union approved to modify the course of the disease rather than just manage its symptoms.\n\nüî¨‚ÄãHow does Lecanemab work?\n‚ÄãAlzheimer's is closely linked to the buildup of beta-amyloid, a protein that forms toxic plaques and damages neurons in the brain. Many previous therapies targeted mature plaques. Lecanemab works differently. It is a monoclonal antibody that binds to and neutralizes beta-amyloid protofibrils‚Äîsmall, soluble, and highly toxic protein aggregates believed to be the primary cause of neuronal damage.\n‚ÄãBy removing these harmful substances early on, Lecanemab helps slow down disease progression, preserving the patient's cognitive functions. üß†‚ú®\n\nüìà‚ÄãKey Findings from Clinical Trials\n‚ÄãThe EMA's decision was based on the results of the Phase III clinical trial, Clarity AD, which showed that patients receiving Lecanemab had a 27% slower rate of cognitive decline compared to the placebo group. While it's not a cure, slowing the disease's progression can translate into months or even years of a better quality of life for patients and their families.\n\nüåç‚ÄãWhat's Next?\n‚ÄãThe EMA's approval is just the beginning. The scientific and medical community now faces the challenge of implementing and monitoring the drug in real-world clinical practice. The availability of the drug in individual EU member states will depend on the decisions of local agencies.\n\n‚ÄãReferences:\n‚ÄãEuropean Medicines Agency (EMA) - Leqembi Approval Information: https://lnkd.in/diMNB3Td\n‚ÄãArticle in The New England Journal of Medicine (NEJM) on the Clarity AD trial: https://lnkd.in/eVVdG8GR\n‚Äã",
        media: [
          {
            type: "IMAGE",
            url: "https://media.licdn.com/dms/image/v2/D4D22AQGNw98CPdUobA/feedshare-shrink_800/B4DZkO6AXzH4Ak-/0/1756891712814?e=1759968000&v=beta&t=yrF8i9fa2f2Rn-HrzkC1DZuWf_g326lPJ6v1h61NL10",
            alt: "Lecanemab illustration",
          },
        ],
        links: [
          {
            url: "https://lnkd.in/diMNB3Td",
            title: "EMA Approval Information",
          },
          {
            url: "https://lnkd.in/eVVdG8GR",
            title: "NEJM Clarity AD trial",
          },
        ],
        hashtags: [
          "Lecanemab",
          "Leqembi",
          "AlzheimersDisease",
          "Neurology",
          "EMA",
          "Breakthrough",
          "Medicine",
          "ClinicalTrials",
          "BridgeMedical",
        ],
      },
      visibility: "PUBLIC",
      permalink:
        "https://www.linkedin.com/posts/bridge-medical-paul-barratt_lecanemab-leqembi-alzheimersdisease-activity-7368991195114483714-l1Mh/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAF6S1E8BDWSdo5lvhJ08mgXomnkB1L5_HSk",
      engagement: {
        likes: 120,
        comments: 15,
        shares: 8,
        views: 2500,
      },
      comments: [],
      sponsored: false,
      language: "en",
      geo: {
        country: "PL",
        city: "Warsaw",
      },
    },
    {
      id: "urn:li:ugcPost:1234567890123456789",
      author: {
        id: "urn:li:organization:987654321",
        name: "Bridge Medical",
        logo: "https://media.licdn.com/dms/image/v2/D4D0BAQGeVzHUMroZgg/company-logo_200_200/company-logo_200_200/0/1716200174821?e=1759968000&v=beta&t=_0zXxkhx5U6Tl33WRw3ylTX_X46i5QjlyLPf2QmSRMY",
        verified: true,
        title: "Medical Consulting",
      },
      created: "2025-09-08T10:15:00Z",
      lastModified: "2025-09-08T10:15:00Z",
      content: {
        text: "üß†‚ÄãLecanemab (Leqembi): A True Breakthrough in Alzheimer's Disease Treatment...\n\nüá™üá∫‚ÄãIn April of this year, the medical world received exciting news: the European Medicines Agency (EMA) approved Lecanemab (marketed as Leqembi) for the treatment of early-stage Alzheimer's disease. This marks a historic moment, as it's the first therapy in the European Union approved to modify the course of the disease rather than just manage its symptoms.\n\nüî¨‚ÄãHow does Lecanemab work?\n‚ÄãAlzheimer's is closely linked to the buildup of beta-amyloid, a protein that forms toxic plaques and damages neurons in the brain. Many previous therapies targeted mature plaques. Lecanemab works differently. It is a monoclonal antibody that binds to and neutralizes beta-amyloid protofibrils‚Äîsmall, soluble, and highly toxic protein aggregates believed to be the primary cause of neuronal damage.\n‚ÄãBy removing these harmful substances early on, Lecanemab helps slow down disease progression, preserving the patient's cognitive functions. üß†‚ú®\n\nüìà‚ÄãKey Findings from Clinical Trials\n‚ÄãThe EMA's decision was based on the results of the Phase III clinical trial, Clarity AD, which showed that patients receiving Lecanemab had a 27% slower rate of cognitive decline compared to the placebo group. While it's not a cure, slowing the disease's progression can translate into months or even years of a better quality of life for patients and their families.\n\nüåç‚ÄãWhat's Next?\n‚ÄãThe EMA's approval is just the beginning. The scientific and medical community now faces the challenge of implementing and monitoring the drug in real-world clinical practice. The availability of the drug in individual EU member states will depend on the decisions of local agencies.\n\n‚ÄãReferences:\n‚ÄãEuropean Medicines Agency (EMA) - Leqembi Approval Information: https://lnkd.in/diMNB3Td\n‚ÄãArticle in The New England Journal of Medicine (NEJM) on the Clarity AD trial: https://lnkd.in/eVVdG8GR\n‚Äã",
        media: [
          {
            type: "IMAGE",
            url: "https://media.licdn.com/dms/image/v2/D4D22AQGNw98CPdUobA/feedshare-shrink_800/B4DZkO6AXzH4Ak-/0/1756891712814?e=1759968000&v=beta&t=yrF8i9fa2f2Rn-HrzkC1DZuWf_g326lPJ6v1h61NL10",
            alt: "Lecanemab illustration",
          },
        ],
        links: [
          {
            url: "https://lnkd.in/diMNB3Td",
            title: "EMA Approval Information",
          },
          {
            url: "https://lnkd.in/eVVdG8GR",
            title: "NEJM Clarity AD trial",
          },
        ],
        hashtags: [
          "Lecanemab",
          "Leqembi",
          "AlzheimersDisease",
          "Neurology",
          "EMA",
          "Breakthrough",
          "Medicine",
          "ClinicalTrials",
          "BridgeMedical",
        ],
      },
      visibility: "PUBLIC",
      permalink:
        "https://www.linkedin.com/posts/bridge-medical-paul-barratt_lecanemab-leqembi-alzheimersdisease-activity-7368991195114483714-l1Mh/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAF6S1E8BDWSdo5lvhJ08mgXomnkB1L5_HSk",
      engagement: {
        likes: 120,
        comments: 15,
        shares: 8,
        views: 2500,
      },
      comments: [],
      sponsored: false,
      language: "en",
      geo: {
        country: "PL",
        city: "Warsaw",
      },
    },
    {
      id: "urn:li:ugcPost:1234567890123456789",
      author: {
        id: "urn:li:organization:987654321",
        name: "Bridge Medical",
        logo: "https://media.licdn.com/dms/image/v2/D4D0BAQGeVzHUMroZgg/company-logo_200_200/company-logo_200_200/0/1716200174821?e=1759968000&v=beta&t=_0zXxkhx5U6Tl33WRw3ylTX_X46i5QjlyLPf2QmSRMY",
        verified: true,
        title: "Medical Consulting",
      },
      created: "2025-09-08T10:15:00Z",
      lastModified: "2025-09-08T10:15:00Z",
      content: {
        text: "üß†‚ÄãLecanemab (Leqembi): A True Breakthrough in Alzheimer's Disease Treatment...\n\nüá™üá∫‚ÄãIn April of this year, the medical world received exciting news: the European Medicines Agency (EMA) approved Lecanemab (marketed as Leqembi) for the treatment of early-stage Alzheimer's disease. This marks a historic moment, as it's the first therapy in the European Union approved to modify the course of the disease rather than just manage its symptoms.\n\nüî¨‚ÄãHow does Lecanemab work?\n‚ÄãAlzheimer's is closely linked to the buildup of beta-amyloid, a protein that forms toxic plaques and damages neurons in the brain. Many previous therapies targeted mature plaques. Lecanemab works differently. It is a monoclonal antibody that binds to and neutralizes beta-amyloid protofibrils‚Äîsmall, soluble, and highly toxic protein aggregates believed to be the primary cause of neuronal damage.\n‚ÄãBy removing these harmful substances early on, Lecanemab helps slow down disease progression, preserving the patient's cognitive functions. üß†‚ú®\n\nüìà‚ÄãKey Findings from Clinical Trials\n‚ÄãThe EMA's decision was based on the results of the Phase III clinical trial, Clarity AD, which showed that patients receiving Lecanemab had a 27% slower rate of cognitive decline compared to the placebo group. While it's not a cure, slowing the disease's progression can translate into months or even years of a better quality of life for patients and their families.\n\nüåç‚ÄãWhat's Next?\n‚ÄãThe EMA's approval is just the beginning. The scientific and medical community now faces the challenge of implementing and monitoring the drug in real-world clinical practice. The availability of the drug in individual EU member states will depend on the decisions of local agencies.\n\n‚ÄãReferences:\n‚ÄãEuropean Medicines Agency (EMA) - Leqembi Approval Information: https://lnkd.in/diMNB3Td\n‚ÄãArticle in The New England Journal of Medicine (NEJM) on the Clarity AD trial: https://lnkd.in/eVVdG8GR\n‚Äã",
        media: [
          {
            type: "IMAGE",
            url: "https://media.licdn.com/dms/image/v2/D4D22AQGNw98CPdUobA/feedshare-shrink_800/B4DZkO6AXzH4Ak-/0/1756891712814?e=1759968000&v=beta&t=yrF8i9fa2f2Rn-HrzkC1DZuWf_g326lPJ6v1h61NL10",
            alt: "Lecanemab illustration",
          },
        ],
        links: [
          {
            url: "https://lnkd.in/diMNB3Td",
            title: "EMA Approval Information",
          },
          {
            url: "https://lnkd.in/eVVdG8GR",
            title: "NEJM Clarity AD trial",
          },
        ],
        hashtags: [
          "Lecanemab",
          "Leqembi",
          "AlzheimersDisease",
          "Neurology",
          "EMA",
          "Breakthrough",
          "Medicine",
          "ClinicalTrials",
          "BridgeMedical",
        ],
      },
      visibility: "PUBLIC",
      permalink:
        "https://www.linkedin.com/posts/bridge-medical-paul-barratt_lecanemab-leqembi-alzheimersdisease-activity-7368991195114483714-l1Mh/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAF6S1E8BDWSdo5lvhJ08mgXomnkB1L5_HSk",
      engagement: {
        likes: 120,
        comments: 15,
        shares: 8,
        views: 2500,
      },
      comments: [],
      sponsored: false,
      language: "en",
      geo: {
        country: "PL",
        city: "Warsaw",
      },
    },
  ]);

  return (
    <div className="space-y-16">
      {/* Header */}
      <section className="relative bg-gradient-to-r from-primary to-primary/80 text-white py-16">
        <div className="absolute inset-0 bg-black/10"></div>
        <div className="relative max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 text-center">
          <h1 className="text-4xl font-bold mb-4">
            Latest Updates from Bridge Medical
          </h1>
          <p className="text-xl max-w-3xl mx-auto">
            Follow our team's insights and experiences in European medical
            device consulting
          </p>
        </div>
      </section>

      {/* LinkedIn-style Posts */}
      <div className="max-w-4xl mx-auto px-4 py-6 space-y-4">
        {posts.length === 0 ? (
          <div className="text-center text-muted-foreground">
            No posts available.
          </div>
        ) : (
          posts.map((post) => (
            <Card key={post.id} className="bg-white">
              <CardContent className="p-0">
                {/* Post Header */}
                <div className="p-4 pb-3">
                  <div className="flex items-start justify-between">
                    <div className="flex items-start space-x-3">
                      <Avatar className="w-12 h-12">
                        <img
                          src={post.author.logo}
                          alt="Logo"
                          className="w-12 h-12 object-cover rounded-full"
                        />
                      </Avatar>
                      <div className="flex-1">
                        <div className="flex items-center space-x-1">
                          <h3 className="font-semibold text-gray-900 hover:text-blue-600 cursor-pointer">
                            {post.author.name}
                          </h3>
                          {post.author.verified && (
                            <div className="w-4 h-4 bg-blue-600 rounded-full flex items-center justify-center">
                              <div className="w-2 h-2 bg-white rounded-full"></div>
                            </div>
                          )}
                        </div>
                        <p className="text-sm text-gray-600">
                          {post.author.title}
                        </p>
                        <p className="text-xs text-gray-500">
                          {new Date(post.created).toLocaleDateString()} ‚Ä¢ üåç{" "}
                          {post.geo.city}, {post.geo.country}
                        </p>
                      </div>
                    </div>
                    <button className="text-gray-400 hover:text-gray-600 p-1">
                      <MoreHorizontal className="w-5 h-5" />
                    </button>
                  </div>
                </div>

                {/* Post Content */}
                <div className="px-4 pb-3">
                  <div className="text-gray-900 whitespace-pre-line leading-relaxed">
                    {post.content.text}
                  </div>
                  {/* Hashtags */}
                  <div className="mt-2 flex flex-wrap gap-2">
                    {post.content.hashtags.map((tag) => (
                      <span
                        key={tag}
                        className="text-xs bg-blue-50 text-blue-700 px-2 py-1 rounded"
                      >
                        #{tag}
                      </span>
                    ))}
                  </div>
                  {/* Links */}
                  <div className="mt-2">
                    {post.content.links.map((link) => (
                      <a
                        key={link.url}
                        href={link.url}
                        target="_blank"
                        rel="noopener noreferrer"
                        className="text-blue-600 hover:underline block text-xs"
                      >
                        {link.title}
                      </a>
                    ))}
                  </div>
                </div>

                {/* Post Image */}
                {post.content.media && post.content.media.length > 0 && (
                  <div className="bg-gray-100 flex items-center justify-center text-gray-500">
                    <img
                      src={post.content.media[0].url}
                      alt={post.content.media[0].alt}
                      className="rounded-lg w-full max-h-96 object-cover"
                    />
                  </div>
                )}

                {/* Engagement Stats */}
                <div className="px-4 py-2 border-t border-gray-100">
                  <div className="flex items-center justify-between text-sm text-gray-600">
                    <div className="flex items-center space-x-4">
                      <span className="flex items-center space-x-1">
                        <div className="w-4 h-4 bg-blue-600 rounded-full flex items-center justify-center">
                          <ThumbsUp className="w-2.5 h-2.5 text-white" />
                        </div>
                        <span>{post.engagement.likes}</span>
                      </span>
                      <span>{post.engagement.comments} comments</span>
                      <span>{post.engagement.shares} shares</span>
                      <span>{post.engagement.views} views</span>
                    </div>
                  </div>
                </div>
              </CardContent>
            </Card>
          ))
        )}
      </div>

      {/* Follow Suggestion */}
      <Card className="bg-white">
        <CardContent className="p-4 text-center">
          <div className="w-16 h-16 bg-blue-600 rounded-full flex items-center justify-center mx-auto mb-3">
            <Users className="w-8 h-8 text-white" />
          </div>
          <h3 className="font-semibold text-gray-900 mb-2">
            Follow Bridge Medical
          </h3>
          <p className="text-sm text-gray-600 mb-4">
            Stay updated with the latest insights from European medical device
            consulting
          </p>
          <Button className="w-full">+ Follow</Button>
        </CardContent>
      </Card>
    </div>
  );
}
